A Phase 1 interventional study of Zavegepant in Healthy, sponsored by Pfizer. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-06.
Sponsored by Pfizer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn about:
This study is seeking participants who:
All participants in this study will receive Zavegepant by nose, once at the study clinic.
The experiences of the participants receiving the study medicine will be looked at. This will help see if the study medicine is safe.
Participants will take part in this study for around 9 weeks. During this time, participants will have 2 study visits at the study clinic and 1 contact over the phone.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving Zavegepant for the treatment phase of the study
Drug: Zavegepant
Participants receiving single dose of Zavegepant 10 mg
Cmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
Maximum plasma concentration (Cmax) was measured.
Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
AUClast of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
AUClast, area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (Clast), was measured.
Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
AUCinf of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
AUCinf, area under the plasma concentration-time curve from time 0 extrapolated to infinite time, was measured.
Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, including untoward findings on physical examinations captured as AEs if any.
Time frame: Day 1 up to maximum of 35 days post single dose administration
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
Time frame: Day 1 up to maximum of 35 days post single dose administration
Number of Participants With Clinically Significant Values of Vital Signs
Time frame: Day 1 up to maximum of 35 days post single dose administration
Number of Participants With Clinically Significant Values of 12-lead ECGs
Time frame: Day 1 up to maximum of 35 days post single dose administration
Tmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
Tmax, time to Cmax, was measured.
Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
t1/2 of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
T1/2, terminal half-life, was measured.
Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
CL/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
CL/F, apparent clearance, was measured.
Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
Vz/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN
Vz/F, apparent volume of distribution, was measured.
Time frame: 0 (pre-dose), 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours post dose on Day 1
A total of 13 participants were enrolled and 12 participants received 1 dose of study intervention, and all 12 participants completed the study.
| Milestone | Zavegepant IN 10 mg |
|---|---|
| Started | 12 |
| Received treatment | 12 |
| Completed | 12 |
| Not completed | 0 |
| Milestone | Zavegepant IN 10 mg |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
Maximum plasma concentration (Cmax) was measured.
| nanogram per milliliter (ng/mL) | Zavegepant IN 10 mg |
|---|---|
| Cmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN | 20.32 ± 114 |
AUClast, area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (Clast), was measured.
| ng*hour/mL | Zavegepant IN 10 mg |
|---|---|
| AUClast of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN | 44.25 ± 122 |
AUCinf, area under the plasma concentration-time curve from time 0 extrapolated to infinite time, was measured.
| ng*hr/mL | Zavegepant IN 10 mg |
|---|---|
| AUCinf of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN | 53.53 ± 128 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, including untoward findings on physical examinations captured as AEs if any.
| Participants | Zavegepant IN 10 mg |
|---|---|
| With all-causality TEAEs | 4 |
| With treatment-related TEAEs | 3 |
| Participants | Zavegepant IN 10 mg |
|---|---|
| Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 1 |
| Participants | Zavegepant IN 10 mg |
|---|---|
| Number of Participants With Clinically Significant Values of Vital Signs | 0 |
| Participants | Zavegepant IN 10 mg |
|---|---|
| Number of Participants With Clinically Significant Values of 12-lead ECGs | 0 |
Tmax, time to Cmax, was measured.
| hour | Zavegepant IN 10 mg |
|---|---|
| Tmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN | 0.584 (0.333 to 1.00) |
T1/2, terminal half-life, was measured.
| hour | Zavegepant IN 10 mg |
|---|---|
| t1/2 of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN | 11.00 ± 1.4929 |
CL/F, apparent clearance, was measured.
| Liter/hr | Zavegepant IN 10 mg |
|---|---|
| CL/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN | 186.8 ± 128 |
Vz/F, apparent volume of distribution, was measured.
| Liter | Zavegepant IN 10 mg |
|---|---|
| Vz/F of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN | 2943 ± 141 |
Collected over Day 1 up to maximum of 35 days post single dose administration. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zavegepant IN 10 mg | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Event | Zavegepant IN 10 mg |
|---|---|
| Laryngeal discomfortRespiratory, thoracic and mediastinal disorders | 1/12 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/12 |
| Nasal mucosal discolourationRespiratory, thoracic and mediastinal disorders | 1/12 |
| Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders | 1/12 |
| Urticaria papularSkin and subcutaneous tissue disorders | 1/12 |
Participants who received study treatments were included in baseline analysis population.
| Age, Customized(Participants) | Zavegepant IN 10 mg |
|---|---|
| <18 Years | 0 |
| 18-25 Years | 3 |
| 26-35 Years | 6 |
| 36-45 Years | 3 |
| >45 Years | 0 |
| Sex: Female, Male(Participants) | Zavegepant IN 10 mg |
|---|---|
| Female | 4 |
| Male | 8 |
| Race/Ethnicity, Customized(Participants) | Zavegepant IN 10 mg |
|---|---|
| Asian | 12 |
| Race/Ethnicity, Customized(Participants) | Zavegepant IN 10 mg |
|---|---|
| Not Hispanic or Latino | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2023 to primary completion in Dec 2023, 1 month.
Results were first posted in Jan 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zavegepant